Cipla announces Q2 FY19 results demonstrating continued momentum across branded markets and progress on US pipeline

Mumbai, November 11, 2018: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for quarter ended September 30, 2018.

Key highlights of the quarter

• R&D investments at ~INR 316cr / ~8% of sales

• Continued growth momentum: Growth in private market [non-tender] segments continues strong across India, the US, South Africa and Emerging Markets

• US business sales trajectory improves with 12% YoY growth driven by contribution from new launches. 7 new approvals in the quarter with multiple limited competition assets getting launched

• Quality Focus: Inspection at Goa plant concludes with minor procedural observations

TS:

India1

• As per IQVIA (IMS) Q2’18, Cipla continued its outperformance growing by 14%

• Performance in key therapeutic areas as follows

• Cipla gained one Rank in Cardiology and now stands at 4th position growing

500bps higher than market at 19%

• Continued leadership position in Respiratory growing at 23%. Cipla’s flagship

inhalation awareness campaign “Berok Zindagi’on a good start

• Urology maintained its leadership position with over 15% market share

SAGA – SOUTH AFRICA, SUB-SAHARAN AFRICA AND GLOBAL ACCESS2

• As per IQVIA (IMS) MAT Aug’18, South Africa business grew at more than double the market at 14% in the private market vs 5% market growth

• As per YTD Aug IQVIA (IMS) data, Cipla became the 3rd largest pharma company in SA private market with 6.3% share

• Closed the Mirren acquisition; working towards successfully integrating the business and driving synergies in fast-growing OTC space

• Successful IPO and listing of Cipla’s subsidiary CiplaQCIL on the Uganda Stock Exchange

NorthNORTHAmerica AMERICA

• DTM [Direct to Market] business saw continued improvement in gross margin through increased contribution from differentiated launches

• 7 approvals in Q2 including Atazanavir, Diclofenac gel and Albendazole

• 5 ANDAs filed during the quarter; on track for 20+ filings in FY19

EUROPE & EMERGING MARKETS

Europe & Emerging Markets

• Biosimilars franchise in the EM: Late stage discussions on-going for various key biosimilar assets across multiple markets

• Signed a commercializing deal for Bevacizumab in Sri Lanka and Nepal.

• Inaugurated Cipla Maroc facility

• FPSM (Fluticasone propionate / Salmeterol) launched in Italy with substitutability status

CONSOLIDATED PROFIT & LOSS STATEMENT

• Includes South Africa, Sub-Saharan and Cipla Global Access business, excludes SA Animal Health ^ Excluding SA Animal Health

* Includes CNV business, Vet (India and SA Animal Health) and other elements of Revenue

BALANCE SHEET

EARNINGS CONFERENCE CALL

The Company will host an Earnings conference call at 1530 hrs IST (1800 hrs SST/HKT, 1000 hrs BST, 0500 hrs US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.cipla.com. Kotak Institutional Equities will host the call.

Corporate Comm India(CCI NewsWire)